Kardigan develops targeted cardiovascular medicines aimed at modifying the underlying drivers of heart disease rather than only managing symptoms. Founded by former MyoKardia executives, it advances a late-stage pipeline that includes therapies for conditions such as genetic dilated cardiomyopathy. Its approach pairs disease biology with clinical responder identification to pursue more personalized heart treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18 | — |
| Q1 2026 | 0 | — | -56.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PDF Solutions, Inc. (PDFS), Sharplink, Inc. (SBET), COMPASS Pathways plc (CMPS), Immunocore Holdings plc (IMCR), Amplitude, Inc. (AMPL), Lakefront Biotherapeutics NV (LKFT)